Mark Roithmayr

CEO, Alzheimer's Drug Discovery Foundation

Mark Roithmayr is Chief Executive Officer, and his primary focus is securing the resources needed to find effective drugs for Alzheimer's disease. Mr. Roithmayr is a seasoned nonprofit executive with experience in both start-ups and mature organizations. His areas of expertise include strategic planning, fundraising, volunteer development, and brand-building. He has helped to increase the ADDF’s revenue three-fold to $60 million and was instrumental in securing Bill Gates, as well as Jeff Bezos and MacKenzie Scott, as donors to the organization’s venture philanthropy efforts.

Mr. Roithmayr was previously Chief Relationship Officer at the Leukemia and Lymphoma Society. There, he helped launch its venture philanthropy initiative, directed its 56 national chapters, and led annual fundraising of over $200 million. Prior to joining the Leukemia and Lymphoma Society in 2013, he served for seven years as president of Autism Speaks. As that organization's first president, he shepherded its growth from a start-up into the world's largest autism research and advocacy organization. During his tenure, Autism Speaks invested more than $170 million in research, resulting in discoveries about the genetic and environmental factors that lead to autism as well as effective treatments for it. Earlier in his career, Mr. Roithmayr held several executive positions with the March of Dimes. He earned a bachelor's degree in communications at Rowan University.

Read more

This Speaker's Sessions

Town Hall
Thursday Oct. 13
2:30–3:15 PM
Watch Replay
Now Live!

Investments in Innovation: The Path to New Alzheimer’s Treatments

Identifying and investing in innovative, impactful therapies is only possible when leading scientists and entrepreneurs are connected and have access to capital. Leaders of influential global investment organizations with a venture-minded approach to drug discovery will discuss their perspectives, resources, and funding opportunities to support and accelerate Alzheimer’s treatments. Key Question: What new drugs, technologies, and breakthrough innovations might benefit all of Us in the next 10 years, and how do we spark investment?

View SessionWatch Replay